Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305547 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,093
- Enrollment target
NCT05305547: Completed Phase 3 study, sponsored by Shionogi.
NCT05305547 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 2,093 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (171% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05305547, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,093 participants
- Enrollment target
Study Summary
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
Primary Outcome
Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.
Interventions
- DRUG Placebo
- DRUG S-217622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,093 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2024-05-24 |
| Phase | Phase 3 |
What the finished NCT05305547 record still lists
NCT05305547 is an interventional study that assigns participants to a tested intervention. Its 2,093 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (171% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05305547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05305547 about?
NCT05305547 is a clinical study titled "A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19". The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
What is the current status of trial NCT05305547?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,093 participants. The study started on 2022-08-03. Estimated completion is 2024-05-24.
What interventions are being tested in trial NCT05305547?
The interventions under investigation include: Placebo (DRUG), S-217622 (DRUG).
Who is sponsoring clinical trial NCT05305547?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05305547's enrollment target sits among peer trials
2,093 99th of 2000 higher than 1,902 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI